Promising. Not approved. Not for sale.
Retatrutide: trial results, FDA timeline and why you can’t buy it yet
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Retatrutide is Eli Lilly’s investigational weekly shot, not FDA-approved as of November 1, 2026, so it has no price per month yet. Lilly says it can’t be legally sold, the FDA says it can’t be compounded, and Lilly plans to submit it to the FDA in Q1 2027.
- Not FDA-approved as of November 1, 2026
- FDA filing: planned for Q1 2027, Lilly says
- Can’t be compounded, the FDA says
Retatrutide at a glance
- What it is
- A once-weekly GIP,
GLP-1 and glucagon “triple agonist” - Maker
- Eli Lilly
- FDA status
- Not approved, as of November 1, 2026
- Studied for
- Obesity, type 2 diabetes, sleep apnea and more
- Can you buy it?
- No. Only in Lilly’s trials or its narrow expanded access program
Want an approved or prescribed option today? Call or text
4.8 out of 5 on Trustpilot, 407 reviews · LegitScript certified
About 3 minutes of health questions. No insurance needed.
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
At a glance
Can you get retatrutide yet?
| Question | Answer |
|---|---|
| Is it FDA-approved? | No, as of November 1, 2026 |
| What is it? | Eli Lilly’s investigational once-weekly shot, acting on GIP, |
| Phase 3 results | Up to 28.3% average weight loss at 80 weeks on 12 mg (TRIUMPH-1), if everyone stayed on treatment |
| When could it be approved? | Not before an FDA review: Lilly plans to submit it in the first quarter of 2027 |
| Can you buy it? | No. Lilly says it can’t be legally sold, and the FDA says it can’t be compounded. Only Lilly’s trials or its narrow expanded access program |
| What can you take now? | Zepbound, Wegovy or Foundayo, or compounded tirzepatide, which isn’t FDA-approved: $139 a month on NexLife’s 12-month plan |
Trial results are for Lilly’s medicine in its trials, not for anything sold online. Checked November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Retatrutide isn’t FDA-approved as of November 1, 2026; Lilly plans to submit it to the FDA in Q1 2027.
- What it is: Eli Lilly’s once-weekly shot that acts on GIP,
GLP-1 and glucagon receptors, a “triple agonist.” - Phase 3 results: 28.3% average weight loss at 80 weeks on 12 mg in TRIUMPH-1, if everyone stayed on treatment.
- You can’t buy it: Lilly says it can’t be legally sold, and the FDA says it can’t be compounded.
- Skip “research” vials: the FDA says they’re of unknown quality and may be harmful.
- NexLife doesn’t offer retatrutide. Compounded tirzepatide is $139 a month on its 12-month plan, at every dose; it isn’t FDA-approved.
The basics
What is retatrutide?
Retatrutide is an investigational once-weekly injection from Eli Lilly, not FDA-approved as of November 1, 2026. It’s one molecule that acts on three hormone receptors, GIP,
Lilly is testing it for obesity, type 2 diabetes, knee osteoarthritis pain, sleep apnea, chronic low back pain, heart and kidney outcomes, and fatty liver disease. How the trial results line up with tirzepatide’s: retatrutide vs. tirzepatide.
Investigational
Not approved for any condition. Lilly says it can’t be legally sold; outside its trials, there’s only a narrow expanded access program.
Once a week
In the trials, people started at 2 mg and stepped up every four weeks to 4, 9 or 12 mg.
Expected filing
Planned for the first quarter of 2027, Lilly says. No approval date or price has been announced.
The results
What were retatrutide’s phase 3 results?
In TRIUMPH-1, reported May 21, 2026, people on 12 mg lost 28.3% of their weight on average at 80 weeks. That’s the average if everyone had stayed on treatment; counting everyone who started, it was 25.0%. TRIUMPH-4 reported 28.7% at 68 weeks. These are results for Lilly’s medicine in trials, not for anything sold online.
| Trial (reported) | Average weight loss | Placebo | Length | Who was in it |
|---|---|---|---|---|
| TRIUMPH-4 (December 11, 2025) | 9 mg: 26.4% 12 mg: 28.7% | 2.1% | 68 weeks | Obesity or overweight with knee osteoarthritis, no diabetes; 445 people |
| TRIUMPH-1 (May 21, 2026) | 4 mg: 19.0% 9 mg: 25.9% 12 mg: 28.3% | 2.2% | 80 weeks | Obesity, or overweight with a weight-related condition, no diabetes; 2,339 people |
| TRIUMPH-2 (July 23, 2026) | 4 mg: 12.7% 9 mg: 19.1% 12 mg: 20.8% | 4.0% | 80 weeks | Obesity or overweight with type 2 diabetes; 1,152 people |
| TRIUMPH-3 (July 23, 2026) | 9 mg: 21.6% 12 mg: 22.6% | 3.2% | 80 weeks | Severe obesity (BMI 35 or more) with heart disease; 1,949 people |
Topline results from Lilly’s news releases, using the “efficacy estimand”: the average if everyone had stayed on treatment. Counting everyone who started, people on 12 mg lost 25.0% in TRIUMPH-1 and 23.7% in TRIUMPH-4. In a TRIUMPH-1 extension, people with a BMI of 35 or more lost 30.3% at 104 weeks. Full results are still being presented and published.
In TRIUMPH-1, 45.3% of people on 12 mg lost at least 30% of their body weight, and 65.3% ended below the BMI threshold for obesity. These are results for retatrutide made by Lilly and given in trials, not for anything sold online.
Safety
What are retatrutide’s side effects?
Mostly stomach and gut effects, as with other medicines in this family. In TRIUMPH-1 (Lilly, May 21, 2026), nausea affected 42.4% of people on 12 mg, against 14.8% on placebo. Dysesthesia, an unusual skin sensation, affected 12.5%, against 0.9%; most cases were mild to moderate. On 12 mg, 11.3% stopped because of side effects, against 4.9% on placebo.
| Side effect | 4 mg | 9 mg | 12 mg | Placebo |
|---|---|---|---|---|
| Nausea | 28.6% | 38.4% | 42.4% | 14.8% |
| Diarrhea | 25.2% | 34.1% | 32.0% | 13.5% |
| Constipation | 23.8% | 25.9% | 26.1% | 10.9% |
| Vomiting | 10.6% | 22.8% | 25.3% | 4.8% |
| Dysesthesia (skin sensation changes) | 5.1% | 12.3% | 12.5% | 0.9% |
| Stopped because of side effects | 4.1% | 6.9% | 11.3% | 4.9% |
From Lilly’s TRIUMPH-1 news release, May 21, 2026.
Timeline
When will retatrutide be approved?
Lilly hasn’t announced an approval date. On July 23, 2026, it said it has the data to support submissions for obesity, knee osteoarthritis pain and sleep apnea. It plans to submit retatrutide to the FDA in the first quarter of 2027. An FDA review takes months after that, so it isn’t expected to be available before then.
TRIUMPH-4, the first phase 3 result: up to 28.7% average weight loss at 68 weeks.
TRIUMPH-1: up to 28.3% average weight loss at 80 weeks.
TRIUMPH-2 and TRIUMPH-3: five positive phase 3 studies in all, Lilly says.
TRANSCEND-T2D-2, its first phase 3 trial against another
GLP-1 medicine: in adults with type 2 diabetes, retatrutide lowered A1C more than Ozempic 2 mg (2.2% vs. 1.8%) and led to more than twice the weight loss (up to 20.9% vs. 9.4% at 80 weeks). The sixth positive phase 3 trial, Lilly says.Planned FDA submission, Lilly said on July 23, 2026.
Every other pipeline drug and its next FDA date: new weight loss drugs 2027.
Safety
Can you buy retatrutide online?
No. Retatrutide isn’t FDA-approved as of November 1, 2026, and Lilly says it “cannot be legally sold or marketed for human use.” So anything sold online as retatrutide, “compounded” or “research” vials included, is unapproved. Here’s what the FDA says about those products:
- The FDA says retatrutide can’t be used in compounding under federal law, so “compounded retatrutide” isn’t a legal product
- It isn’t part of any FDA-approved drug and hasn’t been found safe and effective for any condition, the FDA says
- Vials labeled “for research purposes” or “not for human consumption” are of unknown quality and may be harmful, the FDA says
“Retatrutide and cagrilintide cannot be used in compounding under federal law.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
“The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
Outside its trials, the only route is a narrow expanded access program, which a treating doctor applies for. It’s for adults whose BMI stays at 35 or more despite the highest available dose of a weight-management medicine. They must also have two or more serious obesity-related complications and be unable to join a trial (ClinicalTrials.gov NCT07629401, first posted June 5, 2026). More on these products in research peptides vs. prescribed
Trials
How do you join a retatrutide trial?
Start at ClinicalTrials.gov, which lists the retatrutide studies recruiting near you. Your doctor can tell you if one fits. Trial medicine comes from Lilly and is given under the study’s supervision. Can’t join a trial? For a narrow group of patients, a treating doctor can apply for Lilly’s expanded access program (NCT07629401, first posted June 5, 2026).
Step by step
How do you get retatrutide, step by step?
Retatrutide isn’t approved or for sale. Here’s how to check the two routes that exist today, a trial or expanded access, and what to do meanwhile.
- Check its FDA status. As of November 1, 2026, retatrutide isn’t FDA-approved for any condition. Lilly plans to submit it to the FDA in the first quarter of 2027, and a review takes months after that.
- Skip anything sold online. Lilly says retatrutide “cannot be legally sold or marketed for human use,” and the FDA says it can’t be compounded. “Research” vials are of unknown quality and may be harmful, the FDA says.
- Search for a trial near you. ClinicalTrials.gov lists the retatrutide studies recruiting near you, and your doctor can tell you if one fits. Trial medicine comes from Lilly and is given under the study’s supervision.
- Ask your doctor about expanded access. If you can’t join a trial, a treating doctor can apply for Lilly’s narrow program: adults whose BMI stays at 35 or more despite the highest available dose of a weight-management medicine, with two or more serious obesity-related complications.
- Talk to a provider about today’s options. Zepbound, Wegovy and Foundayo are FDA-approved options you can be prescribed today. Compounded tirzepatide is prescribed too, but it isn’t FDA-approved and wasn’t studied in retatrutide’s trials. A licensed provider decides which fits you.
Only two routes lead to retatrutide today, a trial or expanded access; anything sold online as retatrutide is unapproved.
Waiting for retatrutide? You don’t have to wait to start.
Retatrutide has no approval date: Lilly plans to submit it to the FDA in Q1 2027. Tirzepatide is prescribed today, as FDA-approved Zepbound or as compounded tirzepatide, which isn’t FDA-approved and wasn’t studied in retatrutide’s trials. A licensed provider decides what’s right for you.
- Not approved yet. A filing is expected in early 2027.
- Research vials are risky. The FDA says their quality is unknown.
- A different medicine. Tirzepatide acts on GIP and
GLP-1 ; compounded tirzepatide wasn’t studied in retatrutide’s trials.
Prescribed today. One flat price.
- $139 a month on 12 months, at every dose. Compounded tirzepatide on a 12-month plan ($169 month to month), all in, with no membership.
- A licensed provider decides. Every prescription is a licensed provider’s call, never automatic.
- Named U.S. pharmacies. State-licensed 503A partner pharmacies: Absolute Pharmacy and Boudreaux’s New Drug Store.
Real people, real answers. Questions about what’s coming next? Ask us.
Check my eligibilityCompounded, not FDA-approved: a licensed provider prescribes it only when it offers a significant difference for you.
Options
What can you take instead of retatrutide today?
Today you can be prescribed Zepbound ($299 to $449 per 28 days) or Foundayo ($149 to $299 a month) at LillyDirect, prices read November 1, 2026. Zepbound’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Wegovy’s pen is $349 a month. Compounded tirzepatide is also prescribed today, but it isn’t FDA-approved. Your provider decides which fits you.
| Option | How it works | Self-pay price |
|---|---|---|
| Zepbound (tirzepatide) | Weekly shot; GIP and | $299 to $449 per 28 days at LillyDirect ($449, from 7.5 mg, needs a refill within 45 days; otherwise $499–$699) |
| Wegovy (semaglutide) | Weekly shot or daily pill; | Pen $349 a month; pill $149 to $299 |
| Foundayo (orforglipron) | Daily pill; | $149 to $299 a month at LillyDirect |
| Compounded tirzepatide at NexLife (not FDA-approved) | Weekly shot; GIP and | $139 a month on a 12-month plan, $169 month to month, at every dose Pay less elsewhere? Matched† |
Lilly’s prices read November 1, 2026; Wegovy prices from our price index, November 1, 2026. To compare more options, see the weight loss injections you can get online today.
“Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”
U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers
Vial math
How many units is your tirzepatide or semaglutide dose?
On a compounded vial, the units depend on its strength. Here are the label doses at example strengths, with the math to check your own.
Tirzepatide
| Dose | mL at 25 mg/mL | Units (U-100) | On the label |
|---|---|---|---|
| 2.5 mg | 0.1 mL | 10 units | Starting dose, for 4 weeks |
| 5 mg | 0.2 mL | 20 units | A maintenance dose |
| 7.5 mg | 0.3 mL | 30 units | A step up |
| 10 mg | 0.4 mL | 40 units | A maintenance dose |
| 12.5 mg | 0.5 mL | 50 units | A step up |
| 15 mg | 0.6 mL | 60 units | The maximum, and a maintenance dose |
The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.
Semaglutide
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart.
What would you pay with NexLife?
Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.
Pick one above to see your price.
Prices from each provider’s own site, checked November 1, 2026. Brand-name and compounded medications are different products: compounded medications aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you. Price Match Guarantee† terms apply.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Retatrutide: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What is retatrutide?
An investigational once-weekly injection from Eli Lilly that activates three hormone receptors: GIP,
Is retatrutide FDA-approved?
No. As of November 1, 2026, retatrutide isn’t approved for any condition, and Lilly says it “cannot be legally sold or marketed for human use.” Lilly plans to submit it to the FDA in the first quarter of 2027. Approval would come only after the FDA’s review.
When will retatrutide be available?
Not before an FDA approval. Lilly has said it has the data to support submissions, and that it plans to submit retatrutide to the FDA in the first quarter of 2027. As of November 1, 2026, no approval date has been announced.
How much weight do people lose on retatrutide?
In Lilly’s phase 3 trials, people on 12 mg lost up to 28.3% on average at 80 weeks (TRIUMPH-1). In TRIUMPH-4, it was 28.7% at 68 weeks. Both assume everyone stayed on treatment. Counting everyone who started, people on 12 mg lost 25.0% in TRIUMPH-1. These are trial results for Lilly’s medicine, not for anything sold online.
What are retatrutide’s side effects?
Mostly nausea, diarrhea, constipation and vomiting. Dysesthesia, an unusual skin sensation, was also more common than with placebo. In TRIUMPH-1, 4.1% to 11.3% stopped because of side effects, vs. 4.9% on placebo (Lilly, May 21, 2026). There’s no FDA label yet.
Can I buy retatrutide online?
Not legally. Lilly says it “cannot be legally sold or marketed for human use.” The FDA says products sold “for research purposes” are of unknown quality and may be harmful. Outside its trials, the only route is Lilly’s narrow expanded access program, which a treating doctor applies for.
Is compounded retatrutide legal?
No. The FDA says retatrutide can’t be used in compounding under federal law, so “compounded retatrutide” isn’t a legal product. It isn’t part of any FDA-approved drug, the FDA says. Any pharmacy or website offering it is offering an unapproved drug.
How much will retatrutide cost per month?
There’s no price yet: Lilly hasn’t announced one, and it says retatrutide “cannot be legally sold or marketed for human use.” For comparison, Zepbound’s cost without insurance is $299 to $449 per 28-day supply at LillyDirect (read November 1, 2026); $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699.
How do I join a retatrutide trial?
ClinicalTrials.gov lists the retatrutide studies that are recruiting near you, and your doctor can tell you whether you qualify for one of them. Trial medicine comes from Lilly and is given under the study’s supervision. If you can’t join, a treating doctor can apply for Lilly’s narrow expanded access program.
What is the retatrutide dose?
There’s no approved dose, because retatrutide isn’t FDA-approved. In Lilly’s phase 3 trials, people took it once a week, starting at 2 mg and stepping up every four weeks to 4, 9 or 12 mg. The largest average losses were on 12 mg. The FDA says “research” vials are of unknown quality and may be harmful.
Who qualifies for Lilly’s retatrutide expanded access program?
A narrow group: adults whose BMI stays at 35 or more despite the highest available dose of a weight-management medicine, with 2 or more serious obesity-related complications, who can’t join a trial. A treating doctor applies for it (ClinicalTrials.gov NCT07629401, first posted June 5, 2026).
How does retatrutide compare with Ozempic?
In TRANSCEND-T2D-2, reported October 28, 2026, retatrutide lowered A1C more than Ozempic 2 mg in adults with type 2 diabetes (2.2% vs. 1.8%) and led to more than twice the weight loss (up to 20.9% vs. 9.4% at 80 weeks), Lilly says. Retatrutide isn’t FDA-approved as of November 1, 2026.
Does NexLife offer retatrutide?
No. NexLife doesn’t offer retatrutide: Lilly says it can’t be legally sold, and the FDA says it can’t be compounded. A licensed provider can decide whether compounded tirzepatide is right for you instead: $139 a month on the 12-month plan or $169 month to month, at every dose. It isn’t FDA-approved.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Lilly’s TRIUMPH-1 to -4 results, the FDA’s statements on retatrutide (read November 1, 2026) and Lilly’s filing plan (read November 1, 2026) and its expanded access listing (checked October 25, 2026)
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
Ready to start with something prescribed today?
Compounded tirzepatide at NexLife is $139 a month on a 12-month plan, or $169 month to month, at every dose. A licensed provider decides if it’s right for you.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Eli Lilly and Company. Retatrutide delivered weight loss of up to an average of 71.2 lbs in TRIUMPH-4, news release (December 11, 2025).
- Eli Lilly and Company. Retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial (TRIUMPH-1), news release (May 21, 2026).
- Eli Lilly and Company. Retatrutide successful in two additional phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3), news release (July 23, 2026).
- Eli Lilly and Company. Retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial (TRANSCEND-T2D-2), news release (October 28, 2026).
- HCPLive. Retatrutide meets phase 3 weight-loss endpoints in 2 obesity trials (July 23, 2026).
- Epocrates. Retatrutide heads toward FDA filing after positive phase 3 obesity trial results (July 24, 2026).
- U.S. Food and Drug Administration. FDA’s concerns with unapproved
GLP-1 drugs used for weight loss (updated October 1, 2026). Read November 1, 2026. - ClinicalTrials.gov. Studies of retatrutide.
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
- The New England Journal of Medicine. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1), 2022.
- The New England Journal of Medicine. Once-weekly semaglutide in adults with overweight or obesity (STEP 1), 2021.
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), news release (April 1, 2026).
- Eli Lilly and Company. Zepbound through LillyDirect: self-pay prices for the KwikPen and single-dose vials. Read November 1, 2026.
- Novo Nordisk. What to pay for Wegovy.
- NexLife. Compounded tirzepatide plans.
- Novo Nordisk. Wegovy (semaglutide) prescribing information.
- LegitScript. LegitScript certification record for NexLife.us.
- NexLife. Compounded semaglutide plans.
- Ro: weight loss program pricing. Checked November 1, 2026.
- Hims: Zepbound KwikPen. Checked November 1, 2026.
- Hims: Wegovy pill and pen, with membership. Checked November 1, 2026.
- Mochi Health: FAQs (membership and medication prices). Checked November 1, 2026.
- Embody: compounded tirzepatide, one-month supply. Checked November 1, 2026.
- Embody: compounded semaglutide, one-month supply. Checked November 1, 2026.
- ClinicalTrials.gov: Pre-approval expanded access of retatrutide (LY3437943), NCT07629401, sponsored by Eli Lilly (first posted June 5, 2026). Checked October 25, 2026.
- Lilly Medical: Is there an expanded access program for retatrutide? (last reviewed August 26, 2026). Read November 1, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.